Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease (clinicaltrials.gov) - Aug 18, 2025 - P1 | N=16 | Terminated | Sponsor: Alzeca Biosciences, Inc. | Recruiting ➔ Terminated; A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment
First-in-human • Trial termination • Alzheimer's Disease • CNS Disorders
|